In today’s briefing:
- Mankind Pharma Pre-IPO – RHP Updates – A Mixed Bag
- BioMarin Pharmaceutical Inc.: A Story Of Two Possible Game Changers & Generics Competition – Key Drivers
- Bristol-Myers Squibb.: Pipeline Progress & Cancer Breakthroughs – Key Drivers
- LianBio (LIAN US): 2023 Is Going to Be Data Heavy; Current Cash Runway Raises Commercialization Hope
Mankind Pharma Pre-IPO – RHP Updates – A Mixed Bag
- Mankind Pharma (MP) is now looking to raise around US$500m in its upcoming India IPO.
- MP is a pharmaceutical company engaged in developing, manufacturing and marketing a range of pharmaceutical formulations across various acute and chronic therapeutic areas, as well as several consumer healthcare products.
- We have looked at various aspects of the deal in our earlier notes. In this note, we talk about the updates from its recently filed RHP.
BioMarin Pharmaceutical Inc.: A Story Of Two Possible Game Changers & Generics Competition – Key Drivers
- BioMarin gave a mixed performance in the quarter and failed to meet the revenue expectations of Wall Street despite delivering a double-digit top-line growth.
- Its total revenues for the quarter showed an increase despite the continued erosion of the KUVAN market in the US.
- Moreover, lower KUVAN product revenues are mostly because of generic competition due to the loss of market individuality in the US.
Bristol-Myers Squibb.: Pipeline Progress & Cancer Breakthroughs – Key Drivers
- Bristol-Myers Squibb reported another strong quarter which happened to be an all-around beat.
- The sales of Global Opdivo reflect robust demand for its newly launched and also a core indication of double-digit growth.
- Moreover, Bristol-Myers launched all nine new medicines, which include three first-in-class products.
LianBio (LIAN US): 2023 Is Going to Be Data Heavy; Current Cash Runway Raises Commercialization Hope
- LianBio (LIAN US) is expected to report pivotal data from late-stage trials of its drug candidates as well as file for marketing approval for mavacamten in China in 2023.
- Lead candidate mavacamten has potential blockbuster opportunity in China. LianBio has entered into commercialization agreement with Pfizer for sisunatovir in Mainland China, Hong Kong, Macau, and Singapore.
- With current cash position sufficient to fund operations through the end of 2024, LianBio is well positioned to become a commercial-stage company.
💡 Before it’s here, it’s on Smartkarma
Sign Up for Free
The Smartkarma Preview Pass is your entry to the Independent Investment Research Network
- ✓ Unlimited Research Summaries
- ✓ Personalised Alerts
- ✓ Custom Watchlists
- ✓ Company Data and News
- ✓ Events & Webinars
